Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

SOUTH SAN FRANCISCO, Calif., March 11 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule therapeutics, today reported financial results for the quarter and fiscal year ended December 31, 2007.

Total revenue for the fourth quarter of 2007 was $2.0 million, with a net loss of $8.8 million. Total revenue for the year ended December 31, 2007 was $9.7 million, with a net loss of $38.8 million. As of December 31, 2007, cash, cash equivalents and marketable securities totaled $47.7 million, and debt totaled $2.3 million. Net cash used in operating activities in 2007 was $34.5 million.

Recent Highlights

-- This week at the 39th Annual Meeting on Women's Cancer hosted by the Society for Gynecologic Oncology in Tampa, Florida, Sunesis presented positive interim results from the company's ongoing Phase 2 clinical trial of SNS-595, a novel naphthyridine analog, in advanced platinum-resistant ovarian cancer patients.
-- Sixty-five women have been enrolled and treated with single-agent

SNS-595 at a dose of 48 mg/m2 administered once every three weeks,

with the majority of these women having been enrolled since October.

Forty-five women have sufficient follow up to yield useful safety

results and 35 are evaluable for best response using GOG-RECIST

criteria.

-- In this trial, SNS-595 has demonstrated disease control (defined as

stable disease, partial response or complete response), with 31 of

35 of evaluable patients having best responses of stable disease or

better. Of
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 Unraveling life’s mysteries ... The Archer Family purchased a DNA test ... but ended up with a lifetime of memories, sharing, ... the family members’ DNA genuinely brought the family closer ... search deeper into genetic history and prior to taking ...
(Date:7/10/2014)... POINT, Ind. , July 10, 2014 ... expanded its use of capnography for respiratory ... growing group of healthcare leaders in embracing ... measures how effectively patients are breathing and ... depression occurs. By measuring the amount of ...
(Date:7/10/2014)... 2014   Ceres, Inc . (Nasdaq: ... today financial results for the three months ended May ... Ceres reported that the company and its ... growing season in Brazil, which concluded in June, despite ... evaluation areas for part of the growing season. Yields ...
(Date:7/10/2014)... the basis of psychiatric disorders has been extremely challenging ... risk but are insufficient to cause disease. Now investigators ... Press journal Cell Stem Cell describe a ... risks interact with other risk factors or environmental exposures ... research pinpoints a genetic variant that may predispose individuals ...
Breaking Biology Technology:Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9New strategy could uncover genes at the root of psychiatric illnesses 2
... DCTH ), a medical technology company testing its proprietary ... today that Eamonn P. Hobbs, 51, a member of the Delcath ... CEO of the Company. Mr. Hobbs succeeds Richard Taney who ... serve on the Company,s Board of Directors. , ...
... genetics (Nasdaq: DCGN ) and academic colleagues from ... Nature Genetics the discovery of common genetic risk ... fair and dark complexions alike. deCODE had previously discovered five ... (SNPs) linked to risk of BCC, the most common cancer ...
... , NEW BRUNSWICK, N.J., July 3 Johnson & Johnson (NYSE: ... of its tender offer for all outstanding shares of common stock ... midnight (Eastern time) on July 2, 2009. The offer was ... Kite Merger Sub, Inc. , , The depositary for the ...
Cached Biology Technology:Eamonn Hobbs Appointed President & CEO of Delcath Systems, Inc. 2Eamonn Hobbs Appointed President & CEO of Delcath Systems, Inc. 3It's Not Just the Sun: deCODE Discovers Sequence Variants Affecting Susceptibility to Skin Cancer 2It's Not Just the Sun: deCODE Discovers Sequence Variants Affecting Susceptibility to Skin Cancer 3It's Not Just the Sun: deCODE Discovers Sequence Variants Affecting Susceptibility to Skin Cancer 4Johnson & Johnson Completes Initial Tender Offer for Cougar Biotechnology 2Johnson & Johnson Completes Initial Tender Offer for Cougar Biotechnology 3Johnson & Johnson Completes Initial Tender Offer for Cougar Biotechnology 4
(Date:7/11/2014)... at the National Institute of Standards and Technology ... work more effectively, they often prove that necessity ... the case recently for M. Lorna De Leoz ... growing specialization of glycomics. Glycomics is the study ... that are attached to proteins and lipids and ...
(Date:7/11/2014)... researchers, including scientists from the Max Planck Institute for ... major step in understanding photosynthesis, the process by which ... in its atmosphere and which is therefore crucial for ... The researchers report the first direct visualization of a ... in which a specific protein complex, photosystem II, splits ...
(Date:7/11/2014)... transplantation of mesenchymal stem cells can stimulate neurogenesis in ... Alzheimer,s disease (AD) and improve tissue and function injury ... reported on the therapeutic effect of adipose-derived stem cells ... effect on oxidative injury and neurogenesis in the brain ... School of Life Sciences, Tsinghua University, China transplanted ADSCs ...
Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2
... developing incontinence before middle age is determined by our ... to urinary incontinence, a study of twins at the ... Urinary incontinence is very common, especially among women, with ... life. Incontinence, overactive bladder and other lower urinary tract ...
... oxygen levels in water has applications for oil spills, ... professor at Michigan State University is poised to help ... isn,t new. The challenge, however, has been manufacturing one ... phosphates and biological wastes. Ruby Ghosh, associate professor of ...
... dead Phantom midge larvae ( Chaoborus spp.) may explain ... of fish, acidification and fish death in Swedish lakes. Researchers ... of using lake-bottom sediments to show when and how fish ... restorations in acidified regions. "It is actually just ...
Cached Biology News:Genes an important factor in urinary incontinence 2Oxygen sensor invention could benefit fisheries to breweries 2Dead midges reveal living conditions of fish 2
... antibody raised against a partial ... Immunogen: SF3B2 (NP_006833, 592 ... recombinant protein with GST tag. ... NM_006842 ...
...
Mouse monoclonal antibody raised against a partial recombinant FBXO11. NCBI Entrez Gene ID = FBXO11...
Mouse monoclonal antibody raised against a partial recombinant ZNF155. NCBI Entrez Gene ID = ZNF155...
Biology Products: